0000275053false2019Q3--12-3140546050,00050,00019,33119,20419,33119,204P3YP3Y11.25P90D00002750532019-01-012019-09-30xbrli:shares00002750532019-10-25iso4217:USD00002750532019-09-3000002750532018-12-3100002750532019-07-012019-09-3000002750532018-07-012018-09-30iso4217:USDxbrli:shares00002750532018-01-012018-09-300000275053us-gaap:CommonStockMember2018-12-310000275053us-gaap:RetainedEarningsMember2018-12-310000275053us-gaap:NoncontrollingInterestMember2018-12-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000275053us-gaap:CommonStockMember2019-01-012019-09-300000275053us-gaap:RetainedEarningsMember2019-01-012019-09-300000275053us-gaap:NoncontrollingInterestMember2019-01-012019-09-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000275053us-gaap:CommonStockMember2019-09-300000275053us-gaap:RetainedEarningsMember2019-09-300000275053us-gaap:NoncontrollingInterestMember2019-09-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-3000002750532017-12-3100002750532018-09-300000275053natr:AccruedSeveranceandRentCostsMember2019-09-300000275053natr:AccruedSeveranceandRentCostsMember2018-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2017-07-11xbrli:pure0000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2017-07-112017-07-110000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2019-09-300000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2018-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2017-07-112017-07-110000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-09-300000275053natr:A2012IncentivePlanMember2012-12-310000275053natr:A2012IncentivePlanMember2015-01-012015-12-310000275053srt:MaximumMembernatr:IncentivePlan2009Member2019-09-300000275053natr:TimeBasedStockOptionsMembersrt:MaximumMember2019-01-012019-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-300000275053us-gaap:EmployeeStockOptionMember2018-12-310000275053us-gaap:EmployeeStockOptionMember2019-01-012019-09-300000275053us-gaap:EmployeeStockOptionMember2019-09-300000275053natr:A2012IncentivePlanMember2019-01-012019-09-300000275053natr:A2012IncentivePlanMember2019-07-012019-09-300000275053natr:TimeBasedStockOptionsMember2019-07-012019-09-300000275053natr:TimeBasedStockOptionsMember2018-07-012018-09-300000275053natr:TimeBasedStockOptionsMember2019-01-012019-09-300000275053natr:TimeBasedStockOptionsMember2018-01-012018-09-300000275053us-gaap:EmployeeStockOptionMember2018-01-012018-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-09-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2018-12-310000275053srt:MinimumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MaximumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053srt:DirectorMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053natr:A2012IncentivePlanMembernatr:TimeBasedRestrictedStockUnitsRSUsMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembernatr:A2012IncentivePlanMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembernatr:A2012IncentivePlanMembernatr:NetSalesandOperatingIncomeTargetsMember2019-01-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-07-012018-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2019-09-300000275053us-gaap:RestrictedStockUnitsRSUMember2018-12-310000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-07-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2018-07-012018-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-01-012019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2018-01-012018-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMembersrt:MaximumMember2019-09-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsNetSalesandEBITDAMember2019-09-300000275053srt:MinimumMembernatr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-300000275053srt:MaximumMembernatr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2019-01-012019-09-30natr:segment0000275053natr:NSPAmericasNSPRussiaCentralandEasternEuropeandNSPChinaMember2019-01-012019-03-310000275053natr:SynergyWorldWideMember2019-01-012019-03-310000275053natr:AsiaSegmentMember2019-07-012019-09-300000275053natr:AsiaSegmentMember2018-07-012018-09-300000275053natr:AsiaSegmentMember2019-01-012019-09-300000275053natr:AsiaSegmentMember2018-01-012018-09-300000275053natr:EuropeSegmentMember2019-07-012019-09-300000275053natr:EuropeSegmentMember2018-07-012018-09-300000275053natr:EuropeSegmentMember2019-01-012019-09-300000275053natr:EuropeSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-01-012018-09-300000275053country:CN2019-07-012019-09-300000275053country:CN2019-01-012019-09-300000275053country:CN2018-07-012018-09-300000275053country:CN2018-01-012018-09-300000275053country:US2019-07-012019-09-300000275053country:US2018-07-012018-09-300000275053country:US2019-01-012019-09-300000275053country:US2018-01-012018-09-300000275053country:KR2019-07-012019-09-300000275053country:KR2018-07-012018-09-300000275053country:KR2019-01-012019-09-300000275053country:KR2018-01-012018-09-300000275053natr:OtherCountriesMember2019-07-012019-09-300000275053natr:OtherCountriesMember2018-07-012018-09-300000275053natr:OtherCountriesMember2019-01-012019-09-300000275053natr:OtherCountriesMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:GeneralHealthProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:AsiaSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2019-07-012019-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2018-07-012018-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2019-01-012019-09-300000275053natr:GeneralHealthProductsMembernatr:EuropeSegmentMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:CardiovascularProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2019-07-012019-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2018-07-012018-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2019-01-012019-09-300000275053natr:PersonalCareProductsMembernatr:NorthAmericaSegmentMember2018-01-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:NorthAmericaSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:GeneralHealthProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:ImmunityProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:CardiovascularProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:DigestiveProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:PersonalCareProductsMember2018-01-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2019-07-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2018-07-012018-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2019-01-012019-09-300000275053natr:LatinAmericaAndOtherSegmentMembernatr:WeightManagementProductsMember2018-01-012018-09-300000275053country:US2019-09-300000275053country:US2018-12-310000275053us-gaap:NonUsMember2019-09-300000275053us-gaap:NonUsMember2018-12-310000275053natr:AsiaSegmentMember2019-09-300000275053natr:AsiaSegmentMember2018-12-310000275053natr:EuropeSegmentMember2019-09-300000275053natr:EuropeSegmentMember2018-12-310000275053natr:NorthAmericaSegmentMember2019-09-300000275053natr:NorthAmericaSegmentMember2018-12-310000275053natr:LatinAmericaAndOtherSegmentMember2019-09-300000275053natr:LatinAmericaAndOtherSegmentMember2018-12-3100002750532019-01-010000275053us-gaap:AccountingStandardsUpdate201602Member2019-01-010000275053srt:MinimumMember2019-09-300000275053srt:MaximumMember2019-09-30natr:claim0000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2019-09-300000275053natr:NonIncomeTaxMember2019-09-300000275053natr:NonIncomeTaxMember2018-12-310000275053natr:NonIncomeTaxMembersrt:MinimumMember2019-09-300000275053natr:NonIncomeTaxMembersrt:MaximumMember2019-09-300000275053us-gaap:PendingLitigationMember2019-09-300000275053us-gaap:PendingLitigationMember2018-12-310000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2019-01-012019-09-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MinimumMember2019-09-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MaximumMember2019-09-300000275053us-gaap:SubsequentEventMember2019-10-012019-11-070000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2019-07-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2019-01-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-01-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-07-012019-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2018-07-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMember2018-01-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-07-012018-09-300000275053natr:NaturesSunshineProductsChinaMemberus-gaap:NotesReceivableMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-01-012018-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2019-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2018-12-310000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2019-09-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2018-12-310000275053us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2019-09-300000275053us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2018-12-31natr:product_category0000275053srt:MaximumMember2019-01-012019-09-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
_________________________________________________________________
 
FORM 10-Q 
(Mark One)
 
     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the quarterly period ended September 30, 2019
 
OR
 
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the transition period from            to            .
 
Commission File Number: 001-34483
natr-20190930_g1.jpg 
 
NATURE’S SUNSHINE PRODUCTS, INC.
(Exact name of Registrant as specified in its charter) 
Utah 87-0327982
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
 
2901 Bluegrass Boulevard, Suite 100
Lehi, Utah 84043
(Address of principal executive offices and zip code)
 
(801) 341-7900
(Registrant’s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valueNATRNasdaq Capital Market

 
Indicate by check mark whether the registrant; (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ý  No  o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ý  No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  o
 
Accelerated filer  x
   
Non-accelerated filer  o
 
Smaller reporting company  
  
Emerging growth company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Table of Contents
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes    No  ý.
 
The number of shares of Common Stock, no par value, outstanding on October 25, 2019, was 19,331,365 shares.



Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC.
FORM 10-Q
 
For the Quarter Ended September 30, 2019
 
Table of Contents
 
    
 
    
  
  
  
  
  
  
    
 
    
 
    
 
    
    
 
    
 
    
 
    
 
    
 
    
 
    
 

2

Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
Certain information included or incorporated herein by reference in this report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under “Risk Factors” in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, but include the following:

laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets.
extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
legal challenges to the Company's direct selling program or to the classification of its independent distributors;
impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
the Company’s ability to attract and retain independent distributors;
the loss of one or more key independent distributors who have a significant sales network;
the full implementation of the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;
registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
cybersecurity threats and exposure to data loss;
the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations
reliance on information technology infrastructure;
the effect of fluctuating foreign exchange rates;
liabilities and obligations arising from improper activity by the Company’s independent distributors;
failure of the Company’s independent distributors to comply with advertising laws;
changes to the Company’s independent distributor compensation plans;
geopolitical issues and conflicts;
negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
risks associated with the manufacturing of the Company's products;
uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
changes in tax laws, treaties or regulations, or their interpretation;
actions on trade relations by the U.S. and foreign governments.
product liability claims; and
the sufficiency of trademarks and other intellectual property rights.

All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, we refer to Nature’s Sunshine Products, Inc., together with our subsidiaries, as "we," "us," "our," "our Company" or “the Company.”

3

Table of Contents
PART I FINANCIAL INFORMATION
 
Item 1. FINANCIAL STATEMENTS
 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
 September 30,
2019
December 31,
2018
Assets  
Current assets:  
Cash and cash equivalents$50,530  $50,638  
Accounts receivable, net of allowance for doubtful accounts of $405 and $460, respectively7,488  7,751  
Inventories45,282  42,048  
Prepaid expenses and other5,224  6,388  
Total current assets108,524  106,825  
Property, plant and equipment, net61,052  64,061  
Operating lease right-of-use assets24,890  —  
Investment securities - trading1,166  1,308  
Intangible assets, net546  618  
Deferred income tax assets8,533  9,056  
Other assets10,036  11,148  
Total assets$214,747  $193,016  
Liabilities and Shareholders’ Equity  
Current liabilities:  
Accounts payable$4,061  $5,219  
Accrued volume incentives and service fees19,161  20,562  
Accrued liabilities28,787  34,801  
Deferred revenue1,324  1,197  
Related party note payable1,500  1,530  
Income taxes payable2,516  3,378  
Current portion of operating lease liabilities5,050  —  
Total current liabilities62,399  66,687  
Liability related to unrecognized tax benefits1,463  2,192  
Long-term portion of operating lease liabilities21,061  —  
Deferred compensation payable1,166  1,308  
Long-term deferred income tax liabilities1,498  1,556  
Other liabilities394  705  
Total liabilities87,981  72,448  
Shareholders’ equity:  
Common stock, no par value, 50,000 shares authorized, 19,331 and 19,204 shares issued and outstanding, respectively135,080  133,684  
Retained earnings (accumulated deficit)3,691  (2,072) 
Noncontrolling interest9  63  
Accumulated other comprehensive loss(12,014) (11,107) 
Total shareholders’ equity126,766  120,568  
Total liabilities and shareholders’ equity$214,747  $193,016  
 
See accompanying notes to condensed consolidated financial statements.


4

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited) 
 Three Months Ended
September 30,
 20192018
Net sales$88,524  $88,828  
Cost of sales22,784  23,161  
Gross profit65,740  65,667  
Operating expenses:  
Volume incentives29,862  30,511  
Selling, general and administrative31,177  31,643  
Operating income4,701  3,513  
Other loss, net(1,243) (353) 
Income before provision for income taxes3,458  3,160  
Provision for income taxes2,107  1,821  
Net income1,351  1,339  
Net income (loss) attributable to noncontrolling interests34  (158) 
Net income attributable to common shareholders$1,317  $1,497  
Basic and diluted net income per common share:  
Basic earnings per share attributable to common shareholders$0.07  $0.08  
Diluted earnings per share attributable to common shareholders$0.07  $0.08  
Weighted average basic common shares outstanding19,313  19,164  
Weighted average diluted common shares outstanding19,662  19,382  
 
See accompanying notes to condensed consolidated financial statements.

5

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited) 
 Nine Months Ended
September 30,
 20192018
Net sales$270,520  $267,436  
Cost of sales70,078  70,152  
Gross profit200,442  197,284  
Operating expenses:  
Volume incentives92,177  93,365  
Selling, general and administrative96,048  97,339  
Operating income12,217  6,580  
Other loss, net(985) (1,420) 
Income before provision for income taxes11,232  5,160  
Provision for income taxes5,523  3,550  
Net income5,709  1,610  
Net loss attributable to noncontrolling interests(54) (452) 
Net income attributable to common shareholders$5,763  $2,062  
Basic and diluted net income per common share:  
Basic earnings per share attributable to common shareholders$0.30  $0.11  
Diluted earnings per share attributable to common shareholders$0.29  $0.11  
Weighted average basic common shares outstanding19,291  19,094  
Weighted average diluted common shares outstanding19,618  19,406  

See accompanying notes to condensed consolidated financial statements.
6

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Amounts in thousands)
(Unaudited) 
 Three Months Ended
September 30,
 20192018
Net income$1,351  $1,339  
Foreign currency translation gain (loss), net of tax(656) 12  
Write-off of cumulative translation adjustments595    
Total comprehensive income$1,290  $1,351  
 
Nine Months Ended
September 30,
 20192018
Net income$5,709  $1,610  
Foreign currency translation loss (net of tax)(1,502) (254) 
Write-off of cumulative translation adjustments595    
Total comprehensive income$4,802  $1,356  
 
See accompanying notes to condensed consolidated financial statements.

 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands)
(Unaudited) 
 Common StockRetained Earnings (Accumulated Deficit)Noncontrolling
Interest
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmount
Balance at December 31, 201819,204  $133,684  $(2,072) $63  $(11,107) $120,568  
Share-based compensation expense—  1,529  —  —  —  1,529  
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax127  (133) —  —  —  (133) 
Net income (loss)—  —  5,763  (54) —  5,709  
Other comprehensive loss—  —  —  —  (907) (907) 
Balance at September 30, 201919,331  $135,080  $3,691  $9  $(12,014) $126,766  
 
See accompanying notes to condensed consolidated financial statements.
7

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited) 
 Nine Months Ended
September 30,
 20192018
CASH FLOWS FROM OPERATING ACTIVITIES:  
Net income$5,709  $1,610  
Adjustments to reconcile net income to net cash provided by operating activities:  
Provision for doubtful accounts4  155  
Depreciation and amortization7,533  7,313  
Non-cash lease expense3,989    
Share-based compensation expense1,529  1,458  
Loss (gain) on sale of property, plant and equipment17  (4,000) 
Deferred income taxes474  650  
Purchase of trading investment securities(69) (128) 
Proceeds from sale of trading investment securities392  610  
Realized and unrealized gains on investments(181) (80) 
Foreign exchange losses597  1,250  
Loss on write-off of cumulative translation adjustment595    
Changes in assets and liabilities:  
Accounts receivable152  467  
Inventories(4,074) 462  
Prepaid expenses and other current assets1,065  (420) 
Other assets469  897  
Accounts payable(1,073) 88  
Accrued volume incentives and service fees(1,096) 169  
Accrued liabilities(5,277) 7,949  
Deferred revenue127  (1,334) 
Lease liabilities(3,619) —  
Income taxes payable(880) (32) 
Liability related to unrecognized tax benefits(729) (2,501) 
Deferred compensation payable(142) (378) 
Net cash provided by operating activities5,512  14,205  
CASH FLOWS FROM INVESTING ACTIVITIES:  
Purchases of property, plant and equipment(4,474) (3,959) 
Proceeds from sale of property, plant and equipment  5,072  
Net cash (used in) provided by investing activities(4,474) 1,113  
CASH FLOWS FROM FINANCING ACTIVITIES:  
Principal payments of revolving credit facility(547) (56,853) 
Proceeds from revolving credit facility547  45,508  
Proceeds from related party borrowing  1,000  
Proceeds from the exercise of stock awards60  664  
Tax benefit from stock awards(193) (578) 
Net cash used in financing activities(133) (10,259) 
Effect of exchange rates on cash and cash equivalents(1,013) (110) 
Net (decrease) increase in cash and cash equivalents(108) 4,949  
Cash and cash equivalents at the beginning of the period50,638  42,910  
Cash and cash equivalents at the end of the period$50,530  $47,859  
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes, net of refunds$5,212  $3,700  
Cash paid for interest63  220  
 
See accompanying notes to condensed consolidated financial statements.
8

Table of Contents
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
(1) Basis of Presentation
 
We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who uses the products themselves or resells them to consumers.
 
Principles of Consolidation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of September 30, 2019, and for the three and nine-month periods ended September 30, 2019 and 2018. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019.
 
It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Noncontrolling Interests

Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $34,000 and net loss attributable to the noncontrolling interests of $0.1 million for the three and nine months ended September 30, 2019, respectively. Net losses attributable to the noncontrolling interests were $0.2 million and $0.5 million for the three and nine months ended September 30, 2018, respectively. As of September 30, 2019 and December 31, 2018, noncontrolling interests were $9,000 and $0.1 million, respectively.

Restructuring Related Accruals and Expenses

We recorded $0.4 million and $2.4 million of restructuring related expenses during the three and nine months ended September 30, 2019, respectively. We recorded $0.7 million restructuring related expenses during the three and nine months ended September 30, 2018. Accrued severance and restructuring related costs were $0.5 million and $0.3 million as of September 30, 2019 and December 31, 2018, respectively.

During the second quarter of 2018, we announced the retirement of our Chief Executive Officer. As a result, we recorded $0 and $1.5 million of transition-related expenses during the three and nine months ended September 30, 2018. As of September 30, 2019 and December 31, 2018, accrued transition costs were $0.5 million and $1.0 million, respectively.

During the third quarter of 2019, we wrote-off cumulative translation adjustments from the closure of a market that resulted in a loss of $0.6 million. This loss is included in Other loss, net, within the Condensed Consolidated Statements of Income during the three and nine months ended September 30, 2019.

Recent Accounting Pronouncements
 
We adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842): Accounting for Leases effective January 1, 2019. This update requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. See Note 8 - Leases for additional disclosure of the adoption of Topic 842.

In February 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from
9

Table of Contents
accumulated other comprehensive income to retained earnings. This ASU is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of ASU 2018-02 did not have a material effect on our results of operations, consolidated financial statements and footnote disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

(2) Inventories
 
The composition of inventories is as follows (dollar amounts in thousands):
 
September 30,
2019
December 31,
2018
Raw materials$12,139  $10,410  
Work in progress1,797  1,524  
Finished goods31,346  30,114  
Total inventories$45,282  $42,048  

(3) Investment Securities - Trading
 
Our trading securities portfolio totaled $1.2 million at September 30, 2019, and $1.3 million at December 31, 2018, and generated gains of $8,000 and $70,000 for the three months ended September 30, 2019 and 2018, respectively, and $181,000 and $103,000 for the nine months ended September 30, 2019 and 2018, respectively.
 
(4) Revolving Credit Facility

On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million, that matures on July 11, 2020 (the “Credit Agreement”). We pay interest on any borrowings under the Credit Agreement at LIBOR plus 1.25 percent (3.29 percent and 3.73 percent as of September 30, 2019 and December 31, 2018), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At September 30, 2019, there was no outstanding balance under the Credit Agreement.

The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency, leverage, and minimum EBITDA. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of September 30, 2019, we were in compliance with the debt covenants set forth in the Credit Agreement.

(5) Net Income Per Share
 
Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

10

Table of Contents
Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2019 and 2018 (dollar and share amounts in thousands, except for per share information): 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2019201820192018
Net income attributable to common shareholders$1,317  $1,497  $5,763  $2,062  
Basic weighted average shares outstanding19,313  19,164  19,291  19,094  
Basic earnings per share attributable to common shareholders$0.07  $0.08  $0.30  $0.11  
Diluted shares outstanding:    
Basic weighted-average shares outstanding19,313  19,164  19,291  19,094  
Stock-based awards349  218  327  312  
Diluted weighted-average shares outstanding19,662  19,382  19,618  19,406  
Diluted earnings per share attributable to common shareholders$0.07  $0.08  $0.29  $0.11  
Dilutive shares excluded from diluted-per-share amounts:    
Stock options439  105  439  105  
Anti-dilutive shares excluded from diluted-per-share amounts:    
Stock options218  1,036  243  1,011  

Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.
 
(6) Capital Transactions
 
Share-Based Compensation
 
During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.
 
We also maintain a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares.
 
11

Table of Contents
Stock Options
 
Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.
 
Stock option activity for the nine-month period ended September 30, 2019, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Exercise
Price Per Share
Options outstanding at December 31, 20181,114  $12.23  
Granted25  8.72  
Forfeited or canceled(793) 12.87  
Exercised(27) 2.35  
Options outstanding at September 30, 2019319  11.21  

During the nine months ended September 30, 2019, we granted options to purchase 25,000 shares of common stock under the 2012 Stock Incentive Plan to one member of our Board of Directors. These options were issued with an exercise price of $8.72 per share and a grant date fair value of $3.44 per share, with an expected life of five years, risk-free interest rate of 1.5 percent, and expected volatility of 43.2 percent.

Share-based compensation expense from time-based stock options for the three-month periods ended September 30, 2019 and 2018, was approximately $0.1 million and $0.1 million, respectively. Share-based compensation expense from time-based stock options for the nine-month periods ended September 30, 2019 and 2018, was approximately $0.1 million and $0.2 million, respectively. As of September 30, 2019 and December 31, 2018, there was no unrecognized share-based compensation expense related to the grants described above.
 
At September 30, 2019, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 319,000 shares of common stock was $0.1 million. At December 31, 2018, the aggregate intrinsic value of outstanding and exercisable options to purchase 1,114,000 shares of common stock was $0.2 million.

For the nine-month periods ended September 30, 2019 and 2018, we issued 27,000 and 99,000 shares of common stock upon the exercise of stock options at an average exercise price of $2.35 and $6.10 per share, respectively. The aggregate intrinsic value of options exercised during the nine-month periods ended September 30, 2019 and 2018, was $0.2 million and $0.4 million, respectively. For the nine-month periods ended September 30, 2019 and 2018, the Company recognized $0.1 million and $0.1 million of tax benefits from the exercise of stock options, respectively.

As of September 30, 2019 and December 31, 2018, we did not have any unvested performance-based stock options outstanding.
 
Restricted Stock Units
 
Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At September 30, 2019 and December 31, 2018, there were 81,000 and 80,000 vested RSUs, respectively, granted to the Board of Directors with a restriction period.

 Restricted stock unit activity for the nine-month period ended September 30, 2019, is as follows (amounts in thousands, except per share information):
12

Table of Contents
 Number of
Shares
Weighted Average
Grant Date
Fair Value
Restricted Stock Units outstanding at December 31, 20181,058  $8.87  
Granted333  7.23  
Forfeited(389) 9.88  
Issued(113) 10.73  
Restricted Stock Units outstanding at September 30, 2019889  7.57  
 
During the nine-month period ended September 30, 2019, we granted 333,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $8.59 per share and vest in annual installments over a three-year period from the grant date or according to the restrictions for the Board of Directors noted above. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $4.38 per share and vest upon achieving share-priced targets over a three-year period from the grant date.
 
Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 13.4 percent for a common share.

Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50 percent, and a range of risk-free rates between 2.1 percent and 2.9 percent.

Share-based compensation expense for RSUs for the three-month periods ended September 30, 2019 and 2018, was approximately $0.5 million and $0.3 million, respectively. Share-based compensation expense from RSUs for the nine-month periods ended September 30, 2019 and 2018, was approximately $1.1 million and $1.3 million, respectively. As of September 30, 2019 and December 31, 2018, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.5 million and $1.8 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.9 years.
 
Share-based compensation expense related to performance-based RSUs for the three-month periods ended September 30, 2019 and 2018, was $0.1 million and $0, respectively. Share-based compensation expense related to performance-based RSUs for the nine-month periods ended September 30, 2019 and 2018, was $0.4 million and $0, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $1.9 million of potential share-based compensation expense. We currently expect to recognize an additional $0.9 million of that potential share-based compensation expense.
 
The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 23,000 and 55,000 shares for the nine-month periods ended September 30, 2019 and 2018, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above. 

(7) Segment Information
 
We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.

13

Table of Contents
Historically, our operating segments were based on brand, customer base, geographical operations with three operating business segments under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China), and one operating business segment under the Synergy® WorldWide brand.

During the second quarter of 2019, we realigned into geographic focused operating business segments across brands to further align regional strategies and drive synergies in product, organizational and go-to-market strategies in local markets. Our internal reporting structure was reorganized to support the new reporting segments and the chief operating decision maker now reviews the operating results of the four segments utilizing a geographic focused format. The presentation of the comparative information has been recast to conform to the 2019 presentation.

Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.

Reportable business segment information is as follows (dollar amounts in thousands):
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2019201820192018
Net sales:    
Asia$33,717  $34,063  $102,475  $97,593  
Europe14,640  13,076  45,312  41,601  
North America34,161  35,578  105,304  109,201  
Latin America and Other6,006  6,111  17,429  19,041  
Total net sales88,524  88,828  270,520  267,436  
Contribution margin (1):    
Asia16,236  16,250  48,638  45,891  
Europe4,865  4,035  14,692  13,744  
North America12,169  12,337  37,587  36,929  
Latin America and Other2,608  2,534  7,348  7,355  
Total contribution margin35,878  35,156  108,265  103,919  
Selling, general and administrative expenses (2)31,177  31,643  96,048  97,339  
Operating income4,701  3,513  12,217  6,580  
Other loss, net(1,243) (353) (985) (1,420) 
Income before provision for income taxes$3,458  $3,160  $11,232  $5,160  
_________________________________________

(1)   Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2)  Service fees in China totaled $2.8 million and $7.3 million for the three and nine-month periods ended September 30, 2019, respectively, compared to $2.7 million and $6.7 million for the three and nine-month periods ended September 30, 2018. These service fees are included in selling, general and administrative expenses.

14

Table of Contents
From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine-month periods ended September 30, 2019 and 2018, as follows (dollar amounts in thousands):
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2019201820192018
Net sales:    
United States$31,579  $33,182  $97,734  $101,322  
South Korea15,226  18,271  52,677  52,463  
Other41,719  37,375  120,109  113,651  
 $88,524  $88,828  $270,520  $267,436  

Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2019201820192018
Asia    
General health$9,450  $8,290  $28,287  $23,046  
Immune105  228  462  663  
Cardiovascular9,997  11,927